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ABSTRACT
Introduction: New medication classes are needed to
improve treatment effectiveness in the depressed
phase of bipolar disorder (BD). Extant evidence
suggests that BD is characterised by neural changes
such as dendritic remodelling and glial and neuronal
cell loss. These changes have been hypothesised to
result from chronic inﬂammation. The principal aims of
the proposed research is to evaluate the
antidepressant efﬁcacy in bipolar depression of
minocycline, a drug with neuroprotective and
immune-modulating properties, and of aspirin, at
doses expected to selectively inhibit cyclooxygenase 1
(COX-1).
Methods and analysis: 120 outpatients between 18
and 55 years of age, who meet DSM-IV-TR criteria for
BD (type I or II) and for a current major depressive
episode will be recruited to take part in a randomised,
double-blind, placebo-controlled, parallel-group,
proof-of-concept clinical trial following a 232 design.
As adjuncts to existing treatment, subjects will be
randomised to receive one of the four treatment
combinations: placebo-minocycline plus placebo-
aspirin, active-minocycline plus placebo-aspirin,
placebo-minocycline plus active-aspirin or active-
minocycline plus active-aspirin. The dose of
minocycline and aspirin is 100 mg twice daily and
81 mg twice daily, respectively. Antidepressant
response will be evaluated by assessing changes in
the MontgomeryeAsberg Depression Rating Scale
scores between baseline and the end of the 6-week
trial. As secondary outcome measures, the anti-
inﬂammatory effects of minocycline and aspirin will be
tested by measuring pre-treatment and post-treatment
levels of C reactive protein and inﬂammatory
cytokines.
Ethics and dissemination: Minocycline has been
widely used as an antibiotic in doses up to 400 mg/
day. Low-dose aspirin has been safely used on
a worldwide scale for its role as an antithrombotic and
thrombolytic. The study progress will be overseen by
a Data, Safety and Monitoring Board, which will meet
once every 6 months. Results of the study will be
published in peer-reviewed publications.
Trial registration number: Clinical Trials.gov:
NCT01429272.
INTRODUCTION
The treatment of bipolar depression remains
a major challenge for psychiatry. The US
Food and Drug Administration has not
approved any of the w25 standard antide-
pressants for the treatment of bipolar
depression, partly because these agents have
not been robustly effective in bipolar
disorder (BD) patients.
1 Thus, currently
approved treatments for bipolar depression
include lithium, quetiapine and the combi-
nation of olanzapine and ﬂuoxetine.
2 Other
treatments used include lamotrigine,
conventional antidepressant agents, other
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ARTICLE SUMMARY
Article focus
- Clinical trial testing the efﬁcacy of aspirin
and/or minocycline in the treatment of bipolar
depression.
Key messages
- Extant evidence suggests that mood disorders
are associated with inﬂammation. Aspirin and
minocycline exert anti-inﬂammatory effects and
have shown promise in the treatment of major
depressive disorder.
Strengths and limitations of this study
- The ﬁrst study to assess the efﬁcacy of the
separate and combined effects of aspirin and
minocycline in the treatment of bipolar depres-
sion. Aspirin and minocycline will be used to
augment conventional treatments in type I
bipolar disorder patients, potentially reducing
statistical power.
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Open Access Protocolatypical antipsychotics, pramipexole or riluzole
(reviewed in Nierenberg et al
3). Unfortunately, the
effectiveness of these options also is limited. For
example, in a placebo-controlled study in which subjects
receiving lithium were randomised to receive either
standard antidepressant pharmacotherapy (paroxetine
or imipramine) or placebo, those receiving lithium plus
an antidepressant did not show a signiﬁcant improve-
ment over those receiving lithium plus placebo.
4 Simi-
larly, in the STEP-BD trial, 42 of 179 subjects (23.5%)
receiving a mood stabiliser plus adjunctive antidepres-
sant drug treatment had a durable recovery, which did
not differ signiﬁcantly from 51 of 187 subjects (27.3%)
receiving mood stabiliser plus placebo. Mallinger et al
reported a similar durable recovery rate in BD depres-
sives treated with mood stabiliser plus paroxetine (27%)
but found a higher rate for adjunctive monoamine
oxidase inhibitors (MAOIs; 53%),
5 consistent with the
ﬁndings of previous studies comparing MAOIs versus
imipramine.
67Unfortunately, MAOIs are commonly
unacceptable to patients.
New classes of antidepressant drugs are needed for
bipolar depression. Existing agents exert their primary
actions on monoaminergic systems. The efﬁcacy of these
agents contributed to the monoamine deﬁciency
hypothesis of depression, which continues to receive
empirical support. Nevertheless, the ﬁeld is in the
early stages of a paradigm shift driven by evidence of
dendritic remodelling and neuronal atrophy in animal
models of depression and of reductions in grey matter
volume and glial cell loss at postmortem in BD.
8 The
neurotrophic effects of lithium, coupled with longitu-
dinal studies demonstrating volumetric changes over
time, raise the possibility that mood disorders are
underpinned by a neurotoxic process.
89The ﬁnal
common pathway through which neurotoxic agents
exert their effect is hypothesised to involve excess
glutamatergic signalling.
10
The glutamatergic model of mood disorders is based
on the premise that excessive stimulation of NMDA
glutamatergic receptors results in neuronal atrophy and
apoptosis of glial and/or neuronal cells and, ipso facto,
depression. Evidence for this hypothesis derives from
multiple sources. In preclinical models, riluzole, which
inhibits neuronal release of glutamate, ceftriaxone,
which increases glutamate reuptake, and NMDA receptor
antagonists, such as ketamine, ameliorate behavioural
analogues of depression.
11 In addition, rats bred to be
genetically sensitive to stress show differential expression
of NMDA receptors,
12 and behavioural analogues of
depression are abrogated in NMDA receptor subunit
knockout mice.
13 In humans, increased serum levels of
glutamate that resolve with antidepressant treatment
were reported in MDD and extended to the cerebro-
spinal ﬂuid (CSF) postmortem.
11 Polymorphisms of the
metabotropic glutamate receptor genes, GRM2 and
GRM3, and a haplotype of the glutamic acid decarbox-
ylase (GAD2) gene were associated with MDD.
14 Finally,
ketamine induced a rapid sustained antidepressant effect
in BD
15 16 and riluzole showed promising results in
treatment-resistant depression.
15 16
One potential cause of the disruption in glutamatergic
signalling in BD is dysregulation of the immune system.
Increased levels of proinﬂammatory cytokines such as
interleukin (IL) 6, IL-1b, interferon a (IFNa), tumour
necrosis factor a (TNFa), prostaglandin E2 (PGE2) and
chemokine ligand 2 (CCL2) are consistently observed in
the blood and CSF of patients with mood disorders, both
at baseline and after exposure to stressors.
17 18 Elevated
serum levels of (proinﬂammatory) positive acute-phase
proteins (eg, haptoglobin, a1-antitrypsin, ceruloplasmin,
C reactive protein (CRP)) but reduced levels of negative
acute-phase proteins (eg, albumin and retinal-binding
protein) also are reported in mood disorders.
19e21
Furthermore, treatment of hepatitis C with IFNa is
known to induce the major depressive syndrome and/or
manic symptoms in approximately 40% of patients, and
the efﬁcacy of conventional antidepressant drugs is asso-
ciated with a reduction in inﬂammation.
18 Moreover,
anti-TNF therapy (for psoriasis) can improve mood.
22
Since proinﬂammatory cytokines can alter brain func-
tion, these data are compatible with evidence that an
activated inﬂammatory response system exists in mood
disorders which plays a role in their pathophysiology.
23e26
The overactivity of the hypothalamicepituitarye
adrenal axis in mood disorders may play a role in
inﬂammation since hypersecretion of corticotrophin-
releasing hormone (CRH) activates the transcription
factor, nuclear factor kB (NF-kB). NF-kB regulates the
expression of proinﬂammatory cytokines in immune
cells in the central nervous system (CNS) and periphery
and the expression of genes involved in apoptosis.
27 In
addition, NF-kB may result in the expression of the class
1 major histocompatibility complex, labelling cells for
removal by cytotoxic T cells.
27 Usually, cortisol
suppresses this inﬂammatory response, but chronic
stress appears to desensitise the glucocorticoid receptor
and by extension, the anti-inﬂammatory effects of
cortisol.
27 Cytokines play a role in desensitising the
system to cortisol. For example, IL-1 and TNFa
retard dexamethasone-induced translocation of the
glucocorticoid receptor from the cytoplasm to the
nucleus.
28
The immunologic and glutamatergic models of BD are
complementary because a proinﬂammatory state is one
potential cause of excitotoxicity.
27 Peripheral inﬂamma-
tory signals activate microglia in the brain, inducing an
inﬂammatory cascade of cytokines and free radicals.
Cytokines and reactive oxygen and nitrogen species exert
a direct toxic apoptotic effect on oligodendrocytes.
Potentially through the loss of oligodendrocytes, oxidative
stress can lead to demyelination. Such a process conceiv-
ably may account for the reduction in oligodendroglia
found postmortem in the prefrontal cortex
29 in mood
disorders. The inﬂammatory milieu also compromises
astrocyte function, leading to downregulation of glutamate
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astrocytes, further amplifying inﬂammatory signalling.
27
In addition, cytokines such as IL-1, IL-6 and TNFa
activate indoleamine 2, 3-dioxygenase (IDO). IDO
catalyses the breakdown of tryptophan, the amino acid
precursor of serotonin and an important regulator of T
cell function, into kynurenine (Kyn).
30 Activation of the
Kyn pathway shunts tryptophan away from 5-HT
synthesis, putatively reducing serotonergic transmission.
Kyn is in turn metabolised into quinolinic acid (Quin),
a potent NMDA receptor agonist, and neuromodulator
involved in lipid peroxidation, which can induce
neuronal damage via oxidative stress and over-
stimulation of NMDA receptors.
30 Consistent with
inﬂammation-related shunt towards Kyn metabolism,
the plasma tryptophaneKyn ratio was found to correlate
inversely with striatal total choline (a putative cell
membrane turnover biomarker) in adolescents with
melancholic depression.
31
The messenger RNA (mRNA) transcripts for proin-
ﬂammatory genes appear particularly sensitive for
discriminating BD patients. Microarray gene expression
proﬁles in puriﬁed CD14+ monocytes from whole blood
of BD subjects, offspring of BD parents and healthy
controls (HCs) displayed a distinct mRNA signature
representing genes from inﬂammatory and inﬂamma-
tion-related pathways.
32 The signature showed >80%
sensitivity and speciﬁcity in BD subjects who were not
receiving lithium or antipsychotic drugs (n¼11) and in
affected offspring of a BD parent (n¼13, of whom
10 had only manifested depression). A positive signature
also was present in 17 of 38 unaffected offspring
(45%) versus 13 of 70 healthy children (19%). Cross-
sectional comparisons suggested that lithium and anti-
psychotic drugsdbut not conventional antidepressant
drugsddownregulated expression of most inﬂammatory
genes. Thus, when medicated and unmedicated subjects
were considered together, only 23 of 42 BD patients
(55%) had a positive signature versus seven of 38 HCs
(18%). Notably, the IL-6 mRNA level remained elevated
in medicated BD subjects and did not differ signiﬁcantly
from unmedicated subjects (table 1), suggesting that this
assay identiﬁes a proinﬂammatory diathesis even in
treated cases.
Minocycline is a second-generation tetracycline that may
prevent both glutamate-induced excitotoxicity and cytokine-
induced inﬂammation in the CNS and periphery
Minocycline has high lipophilicity enabling efﬁcient
transfer across the blood-brain barrier (BBB)
33dits
concentration in CSF reaches 11%e56% of plasma
concentrations.
34 Minocycline inhibits the microglia-
mediated release of proinﬂammatory cytokines IL-1b,
TNFa, IL-6 and p38,
35 while promoting release of the
anti-inﬂammatory cytokine, IL-10.
34 Moreover, minocy-
cline inhibits matrix metalloproteinases, which process
cytokines such as TNFa and IL-1b into their biologically
active forms.
35 Minocycline is also an effective scavenger
of proapoptotic reactive oxygen species and protects
against excitotoxicity by preventing glutamate-induced
activation of nitric oxide synthase.
36 Nitric oxide facili-
tates glutamate release from presynaptic neurons and
inhibits glial glutamate transporters, amplifying gluta-
matergic signalling and contributing to excitotoxic cell
death.
10 Minocycline also upregulates a key molecular
factor in the apoptosis pathway, B cell CLL/lymphoma 2
(BCL-2),
37 an effect shared by lithium, valproate
38 and
certain antidepressant drugs.
39 BCL-2 represses
apoptosis induced by cytotoxic insults.
40 Conceivably,
minocycline may additionally reduce inﬂammation
indirectly by blocking the translocation of bacteria across
the intestinal barrier. In mice exposed to a social stressor,
bacteria translocated across the intestinal barrier stimu-
lating the release of circulating cytokines, such as IL-6,
and increasing microbicidal activity via inducible nitric
oxide synthase.
41 Additionally, stress induced a change
in the community structure of the microﬂora in the
cecum with a decrease in the relative abundance of
bacteria in the genus Bacteroides and an increase in the
relative abundance of bacteria in the genus Clostridium.
Notably, these effects were blocked by pre-treatment with
a broad-spectrum antibiotic.
41
Minocycline has neuroprotective and anti-inﬂammatory
properties
Minocycline prevents glutamate-induced apoptosis of
neurons in vitro,
42 prevents ischaemia-induced activa-
tion of microglia in gerbils,
43 increases hippocampal
neuron survival,
44 reduces lesion volume and improves
Table 1 Magnitude of difference in messenger RNA expression between mood disordered and healthy control (HC) samples
from Padmos et al,
32 showing selected transcripts in unmedicated subjects versus HCs, relative to that of medicated BD
subjects
Gene symbol
Unmedicated BD versus HC Medicated BD versus HC Affected offspring* versus HC
Fold change p Value Fold change p Value Fold change p Value
PDE4B 13.73y <0.001 3.42 <0.001 5.79 <0.001
IL-6 37.92 0.005 9.56 0.006 935.7 <0.001
CCL20 55.49 0.006 6.02 0.10 400.1 <0.001
Sample sizes: unmedicated BD n¼11, medicated BD n¼31, affected offspring n¼13, HCs n¼25 for comparisons against BD adults, n¼70 for
comparisons of offspring.
*Affected with respect to having manifested either a depressive or a manic episode.
yDifference signiﬁcant between unmedicated versus medicated BD samples.
BD, bipolar disorder; CCL20, chemokine ligand 20IL-6, interleukin 6; PDE4B, phosphodiesterase type 4B.
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injury
45 and in fragile X syndrome,
46 reduces proin-
ﬂammatory cytokine expression and improves neuro-
logical function and locomotor activity in rats with spinal
cord injury,
47 attenuates MDMA-induced neurotoxicity
of serotonin and dopamine systems in the cerebral
cortex and hippocampus of mice,
48 reduces inﬂamma-
tion in a rat model of rheumatoid arthritis (RA),
49 and
delays disease progression and demyelination in rodent
models of encephalitis,
50 amyotrophic lateral sclerosis
51
and Huntington’s disease (HD).
52 Based on these data,
minocycline was employed and has shown promise as
a therapeutic agent in human diseases including HD,
53
RA
54 and stroke.
55
Minocycline has been used to treat psychiatric disorders
Miyaoka et al
56 discussed two patients with catatonic
schizophrenia who beneﬁted from minocycline. This
group then conducted a 4-week trial with minocycline
(150 mg/day) in 22 patients with schizophrenia to eval-
uate its efﬁcacy as an adjunct to antipsychotic drugs.
57
Patients showed a signiﬁcant improvement in positive
and negative symptoms. Levkovitz et al
58 recently studied
54 patients with early-stage schizophrenia treated for
6 months with antipsychotic medication and either
minocycline (200 mg/day) or placebo in a double-blind
trial. Minocycline was associated with a reduction in
negative symptoms and improved attention/memory.
The efﬁcacy of minocycline has not been formally
tested in mood disorders. In rodents, minocycline
reduced immobility during the forced swim test,
59 and
co-administration of minocycline synergised the antide-
pressant-like actions of desipramine (but not ﬂuoxe-
tine).
60 Minocycline also abrogated the depression-like
behaviour of rodents exposed to lipopolysaccharide
(LPS).
61 Levine et al
62 presented the case of a 66-year-old
woman with severe BD, who observed that the tetracy-
cline she took for an infection alleviated her depression.
When her depression returned post-treatment, minocy-
cline was reinitiated (150 mg/day). After 1 week, her
HAM-D score fell from 25 to 8.
Aspirin (acetylsalicylic acid) also holds potential efﬁcacy
in BD
The second aim of this study is to assess the antidepres-
sant efﬁcacy of acetylsalicylic acid (ASA) in bipolar
depression. Using a 232 design, we will obtain data
providing estimates of the effect size of ASA relative to
placebo, ASA relative to minocycline and ASA in
combination with minocycline relative to placebo. These
data also will explore the speciﬁcity of any effect found
for minocycline. The clinical use of low-dose ASA
primarily has been driven by its role as an antithrombotic
and thrombolytic. Given the exaggerated death rate from
cardiovascular (CV) events in BD, this action potentially
is advantageous in the management of BD. Nevertheless,
the recent literature also supports a role for low-dose ASA
in the management of the mood disorder itself, speciﬁ-
cally in the amelioration of depressive symptoms.
The mechanism of ASA relates to its capacity to inac-
tivate irreversibly the cyclooxygenase (COX) activity of
prostaglandin (PG) H-synthase-1 and PGH-synthase 2
(referred to as COX-1 and COX-2, respectively).
Although ASA has a short half-life (15e20 min), ASA’s
permanent inhibition of COX-1 allows once daily dosing
for anucleate platelets. In contrast, because nucleated
cells rapidly regenerate this enzyme, a shorter dosing
interval is required to persistently impact COX activity in
cells that mediate inﬂammatory processes. Moreover,
ASA is 50- to 100-fold more potent in inhibiting platelet
COX-1 than monocyte COX-2 activity,
63 so there is nearly
a 100-fold variation in the daily dose of aspirin, as higher
doses are used to target COX-2 in the management of
treating peripheral inﬂammation (eg, arthritis) or pain.
As reviewed below, preliminary evidence obtained in BD
suggests beneﬁcial effects are achieved using ASA in low
doses, where aspirin would inhibit COX-1 but not COX-2.
Aspirin has neuroprotective and anti-inﬂammatory
properties
In the brain, recent data indicate that genetic manipu-
lation of COX-1 and COX-2 differentially modulate
leucocyte recruitment during neuroinﬂammation and
suggest that reduction of COX-1 activity is neuro-
protective, whereas reduction in COX-2 activity is detri-
mental, during a primary neuroinﬂammatory response
(reviewed in Choi et al
64). Choi et al
64 propose that these
distinct roles reﬂect the predominant localisation of
COX-1 in microglia, which play a major role in medi-
ating neuroinﬂammation, in contrast to the predomi-
nant localisation of COX-2 in pyramidal neurons. For
example, Choi et al
65 examined the effects of COX-1 or
COX-2 deﬁciency on intracerebroventricular LPS-
induced neuroinﬂammation by comparing COX-1
( / ) and COX-2 ( / ) knockout mice with wild-type
(WT) (+/+) control animals. After LPS, leucocyte inﬁl-
tration and inﬂammatory response were attenuated in
the COX-1 ( / ) mice but increased in the COX-2
( / ) mice compared with WT controls. In another
study, Choi et al
66 examined the effect of COX-1 genetic
deletion on the inﬂammatory response and neuro-
degeneration induced by b-amyloid and found that in
COX-1 ( / ) mice, the Ab1-42-induced inﬂammatory
response and associated neuronal damage were attenu-
ated compared with WT mice. Compatible with these
results, in pharmacoepidemiological studies investi-
gating whether chronic non-steroidal anti-inﬂammatory
drug (NSAID) use reduced the risk of developing
Alzheimer’s disease (AD), indomethacin, a preferential
COX-1 inhibitor, showed beneﬁcial effects, while COX-2
selective inhibitors failed to show any beneﬁcial effect
in AD patients with mild-to-severe cognitive impairment.
These data suggest the hypothesis that inhibition
of COX-1 activity may be a valid therapeutic strategy
to reduce the cerebral inﬂammatory response and
neurodegeneration in neuropsychiatric diseases in
which neuroinﬂammatory components play a role in
pathophysiology.
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beneﬁcial in BD more speciﬁcally because of their ability
to downregulate activity in the brain arachidonic acid
(AA) cascade by interfering with phospholipase A2
(PLA2) and/or COX function. In rodents, Rapoport
and colleagues
67e69 demonstrated that conventional
mood stabilisers decrease the AA turnover in phospho-
lipids and the expression of PLA2 and/or COX enzymes.
The PLA2 and COX enzymes catalyse, respectively,
release of AA from membrane phospholipid and AA
conversion to eicosanoids such as prostaglandin E2 and
thromboxane B2. The AA cascade is involved in neuro-
receptor-initiated signalling and can be pathologically
upregulated by neuroinﬂammation and excitotoxicity.
Nevertheless, aspirin has additional mechanisms that
may underlie beneﬁts in neuropsychiatric illness. While
low-dose aspirin downregulates AA cascade activity via
inhibition of COX-1 activity, in higher doses, it also
downregulates COX-2 gene transcription, increases
levels of lipoxygenase-derived eicosanoids, such as the
anti-inﬂammatory lipoxin A4, and acetylates COX-2
protein to a modiﬁed enzyme that can convert unes-
teriﬁed AA to anti-inﬂammatory mediators such as 15-
epi-lipoxin A4 (reviewed in Stolk et al
70). The acylated
enzyme also can convert docosahexaenoic acid (DHA)
to 17-(R)-OH-DHA, which, like its metabolites di(R)-OH-
DHA (neuroprotectin (R) D1) and tri(R)-OH-DHA
(resolvin (R) D1), is highly anti-inﬂammatory (reviewed
in Stolk et al
70). Lithium given chronically to rats with
LPS-induced neuroinﬂammation also increases the
brain concentration of 17-OH-DHA. Thus, there may
be a synergy between aspirin and lithium in forming
anti-inﬂammatory brain DHA metabolites.
Aspirin appears effective in preliminary studies of mood
disorders
Pharmacoepidemiological data in BD supportive of
these hypotheses were published by Stolk et al.
70 Using
the Netherlands-based PHARMO Record Linkage
System (which connects pharmacy dispensing records to
hospital discharge records of >2 million individuals
since 1985), these researchers tested whether NSAIDs or
glucocorticoids would ameliorate bipolar symptoms. The
target sample consisted of 5145 patients receiving
lithium (mean age¼48.6615 years; mean duration of
lithium use¼847 days), based upon the assumption
that lithium treatment is relatively speciﬁc to individuals
with BD. The main outcome measure was a calculated
incidence density of medication events (change in the
type or numbers of psychotropic medications prescribed
or increase (>30%) in the psychotropic drug dose).
Subjects receiving low-dose (#80 mg/day) aspirin were
17% less likely to have a medication event, a ﬁnding that
remained signiﬁcant after adjusting for age, sex, chronic
disease score and healthcare utilisation. This effect was
selective for low-dose ASA. In contrast, high-dose aspirin
or non-selective NSAIDs (ie, regimens expected to
inhibit both COX-1 and COX-2), selective COX-2
inhibitors and glucocorticoids did not produce a statisti-
cally signiﬁcant protection. Instead, the co-administra-
tion of non-selective NSAIDs and glucocorticoids was
associated with statistically signiﬁcant increases in
medication events, suggesting destabilisation of bipolar
illness. The ﬁnding that low-dose aspirin decreased the
number of medication events was particularly note-
worthy since aspirin does not signiﬁcantly augment
serum lithium levels in contrast to selective COX-2
inhibitors, which can raise lithium levels.
71 These
preliminary observations thus appeared consistent with
the hypothesis that COX-1 inhibitors can reduce
neuroinﬂammatory processes and thus beneﬁt BD
patients.
Notably, the observation that beneﬁcial effects in BD
were conferred by low-dose ASA, but not by non-selective
COX inhibitors, COX-2 inhibitors or glucocorticoids,
appeared inconsistent with the hypothesis that drugs
that downregulate AA cascade activity in general hold
therapeutic potential in BD. Thus, the putative neuro-
protective effects associated with COX-1 inhibition may
contribute speciﬁcally to the beneﬁts of low-dose aspirin
in BD observed by Stolk et al For example, as reviewed
above, aspirin and lithium may exert synergistic effects
in forming anti-inﬂammatory brain DHA metabolites
(reviewed in Stolk et al
70).
Other data suggest that aspirin exerts antidepressant
effects within the context of MDD or CV illness. Mend-
lewicz et al
72 examined the effect of aspirin augmentation
of conventional antidepressant pharmacotherapy in 24
patients with MDD who had proven non-responsive after
4 weeks of selective serotonin reuptake inhibitor (SSRI)
treatment. Participants were treated openly during the
subsequent 4 weeks with aspirin 160 mg/day in addition
to their SSRI regimen. The combined administration of
SSRI plus aspirin was associated with a response rate of
52.4%. Remission was achieved in 43% of the total
sample and 82% of the responder sample. In the
responder group, a signiﬁcant improvement was
observed within week 1 and this beneﬁt persisted
through day 28. In another study, Ketterer et al
73 reported
that in 174 men undergoing coronary angiography (of
whom 99 were taking low-dose aspirin), aspirin use was
associated with less depression and anxiety symptoms.
In contrast, a preliminary study of the selective COX-2
inhibitor, celecoxib, was negative in bipolar depres-
sion,
74 potentially compatible with the negative results
of COX-2 inhibitors reported by Stolk et al.
70 In a double-
blind, randomised, add-on clinical trial of celecoxib in
patients (n¼28) studied during a depressed or mixed
episode of BD, no signiﬁcant difference was observed
between the celecoxib and placebo add-on groups at
study end point.
74 These results contrasted with those
obtained using celecoxib in unipolar depression,
however. In MDD, celecoxib augmentation of either
reboxetine
75 or ﬂuoxetine
76 was associated with a signif-
icant therapeutic effect on depressive symptoms in
randomised, double-blind, add-on clinical trials.
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Participants
One hundred and twenty male or female outpatients
between 18 and 55 years of age who meet DSM-IV-TR
criteria for BD (type I or II) and for a current major
depressive episode will be recruited. The depressive
syndrome must have been present for at least 4 weeks
and the minimum threshold for depression severity will
be set at a 17-item HAM-D score $18. Subjects will
provide written informed consent as approved by the
Western Institutional Review Board (IRB).
Concurrent medications
At study entry, type I BD subjects must have been taking
a stable dose of a mood-stabilising medication (lithium,
valproate, carbamazepine, lamotrigine, antipsychotic
agents) for at least 4 weeks, dosed clinically to target the
therapeutic range. Type II BD subjects will be included
irrespective of whether they present on a mood stabiliser.
To investigate the utility of this augmentation strategy in
the population for whom minocycline is most likely to
prove therapeutically relevant, volunteers receiving
stable doses of mood stabilising, antipsychotic, antide-
pressant and/or anxiolytic drugs for at least 4 weeks will
be included. However, volunteers who currently are
receiving more than four psychotropic medications in
a daily regimen will be excluded since this condition may
signify a more brittle or complex clinical state. Subjects
may remain in psychotherapy or have no psychosocial
intervention. Volunteers will be excluded if they
currently are receiving medications likely to have adverse
interactions with minocycline or aspirin, including
NSAIDS, warfarin, digoxin, penicillins and isotretinoin
products.
For participants who enter the study, the preferred
strategy will be for subjects to maintain the same
regimen of concurrent medications throughout the 6-
week study so that only the study drug regimen will be
altered per protocol. Nevertheless, changes to concur-
rent medications will not affect study status, so long as
the medication change does not target a depressive or
manic symptom. If changes to concurrent medication
regimens are clinically required to address worsening
depressive symptoms or the development of manic
symptoms, then the subject will be dropped from
the study.
Study design
Patients will participate in a randomised, double-blind
placebo-controlled trial with a 232 design. As adjuncts to
existing treatment, subjects will receive placebo-minocy-
cline plus placebo-aspirin, active-minocycline plus
placebo-aspirin, placebo-minocycline plus active-aspirin,
or active-minocycline plus active-aspirin. The random-
isation sequences will be determined by a research staff
member who is not obtaining clinical information from
the research subject and will be assigned by subject
number at consenting. A restricted randomisation
(permuted block randomisation) method will be used in
which subjects are randomly allocated to each block
(n¼30) to ensure that equal numbers of participants
receive each drug/placebo combination. In order to
ensure that experimental group assignment is not
skewed across the two trial sites, the study progress will
be monitored by individuals who are not involved in the
data collection, and in the case of ‘drift’, adjustments will
be made as necessary.
The trial will be conducted over 6 weeks and will
comprise seven assessment sessions (ﬁgure 1). The
subject will be seen at the prescribed time intervals
within a window of two business days on either side of
visit target date to complete the speciﬁed visits.
At each session, a clinical assessment will be conducted
using the rating scales listed below, and treatment side
effects will be assessed and rated for severity. To preserve
the rater blind, the research staff member who conducts
the clinical ratings will not be the research staff member
who assesses the presence of side effects and will remain
blind to the information pertaining to side effects.
Subjects who experience severe adverse effects or who
develop treatment-associated hypomania or mania will
be dropped from the study, instructed to discontinue the
study medication and referred for appropriate clinical
management of these adverse events.
The primary outcome measure will be the change in the
MontgomeryeAsberg Depression Rating Scale (MADRS)
scores at the seventh assessment session (week 6).
Medication
This pilot proof-of-concept study will adhere to the
dosing limits and route of administration for the Food
and Drug Administration indications for minocycline’s
and aspirin’s use in other conditions (thus an investi-
gational new drug (IND) is not required). A ﬁxed dose
design will be followed, and all medications will be
administered via the p.o. route. The pilot data extant for
both study drugs support an onset of improvement
within 2 weeks, so the 6-week study duration is expected
to provide sufﬁcient time to detect an antidepressant
effect, to provide information about the persistence of
the antidepressant effect over about 1 month from the
anticipated onset of effect and to minimise dropouts.
For minocycline, the starting dose will be 100 mg twice
daily (total daily dose¼200 mg). This dose of 100 mg
twice daily has been shown by a substantial literature to
produce consistent anti-inﬂammatory effects in RA and
other inﬂammatory disorders. This also is the dose used
in a recent schizophrenia treatment trial.
58 The associ-
ated placebo capsules match the appearance of the
100 mg minocycline capsule.
The starting dose of aspirin will be 81 mg p.o. twice
daily. This dose is sufﬁcient to inhibit COX-1 and
appeared beneﬁcial in stabilising the course of BD in the
pharmacoepidemiological study of Stolk et al.
70 When
aspirin is used as an anti-platelet drug, once daily dosing
is sufﬁcient since anucleate platelets do not produce
enough COX-1 to overcome the irreversible inhibition
of COX-1 within a 24 h period. In contrast, in nucleated
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required to persistently inhibit COX-1. Thus, we will
administer the dose in a twice daily regimen, according
to the guidelines described above. A total daily dose of
160 mg was administered in the preliminary study, which
reported that aspirin signiﬁcantly augmented the anti-
depressant effects of ﬂuoxetine in MDD.
72 The relevant
placebo matches the appearance of the aspirin tablet.
Participants will be advised that one of the study drugs
may reduce the efﬁcacy of oral contraceptives and to
avoid taking the study drugs within 3 h of iron products
or of antacids containing calcium, magnesium or
aluminium. They also will be advised that one study drug
can increase their risk for bleeding during surgical
procedure or if combined with other drugs or herbal
preparations that reduce haemostasis.
Compensation
Participants will be compensated for participation in the
amount of $300.00.
Treatment compliance
To enhance compliance, study participants will be given
an information sheet to take home detailing the proce-
dure to be followed in the case of a missed dose and
requesting that this information be recorded for the
investigators. The number of capsules and tablets
remaining in each supply given to the patients will also be
counted to evaluate treatment compliance. In cases where
treatment compliance is poor, subjects will be excluded
from the data analysis, using conventional criteria for
deﬁning adequate compliance in a clinical trial.
Psychiatric assessment and clinical ratings
Patients will be evaluated and followed in the outpatient
clinics at Laureate Institute for Brain Research (LIBR) or
Oklahoma University School of Community Medicine in
Tulsa, Oklahoma, or at the University of Kansas Medical
Center Research Institute (KUMCRI) in Wichita, KS.
The diagnosis of BD will be established using DSM-IV-TR
criteria on the basis of an unstructured interview
conducted by a psychiatrist and the MINI-Plus adminis-
tered by trained psychiatric interviewers. The following
rating scales will be administered: MADRS, Quick
Inventory of Depressive Symptomatology (QUIDS; 16
item), Hamilton Anxiety Rating Scale (HAM-A), Young
Mania Rating Scale (YMRS), Universal Fagerstrom (to
assess nicotine use), Hollingshead Socioeconomic Scale,
Sheehan Disability Scale and the Family Interview for
Genetic Studies. Medical assessment will include a phys-
ical examination, electrocardiogram, complete blood
count, electrolytes and liver function assays (SMA 20),
thyroid panel and urinalysis, serum drug and pregnancy
tests at study entry and study completion. At each follow-
up session, the MADRS, HAM-A, YMRS and Clinical
Global Impressions (CGI) scale will be repeated. Physical
and psychiatric symptoms will be evaluated and recorded
in order to measure the side effect proﬁles of minocy-
cline and aspirin. Participants will be questioned about
adverse reactions, including dizziness, photosensitivity,
hyperpigmentation, gastrointestinal (GI) distress or
bleeding at each assessment, and will be withdrawn from
the study if medically necessary. Vital signs will be
measured at entry and at each session.
Immune system measures
The activity of peripheral cytokines correlates with
inﬂammatory processes in the CNS. Peripheral cytokines
cross the BBB and can propagate signals across the BBB
in the form of small, freely diffusible lipophilic mole-
cules such as prostaglandins, which induce the produc-
tion of cytokines from glia.
77 The measurement of
peripheral markers of inﬂammation thus serves as
a valid, if indirect assessment of CNS inﬂammation.
Figure 1 Schematic of study
design. Each session number
(total of seven) is encircled, with
the timing between sessions
indicated in weeks with a two
business day window on either
side of visit target date to complete
the visit. Session 1 is the baseline
(green star) and session 7 is the
study end (purple star). Peripheral
blood will be sampled at baseline
and study end to assay markers of
inﬂammation. The study duration
is 6 weeks.
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outcome, blood will be sampled for testing plasma and
whole blood peripheral blood monocyte (PBM)-based
markers of inﬂammation at baseline and study end.
These markers will include 10 cytokine proteins (IL-1b,
IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IFNg and
TNFa), high-sensitivity (hs) CRP and RNA expression of
candidate genes from peripheral blood monocyte cells
(PBMCs). Candidate genes include IL-6, TNF and IRF5
(a factor that mediates monocyte polarisation). The 10
inﬂammation-related cytokines and the PBMC mRNA
will be assayed from plasma at baseline and study end.
We selected the markers IL-6, TNF and CRP because
they are the most widely implicated in mood disorders.
The other cytokines included in the cytokine bead array
assays are measured simultaneously with IL-6 and have
all been implicated in the general regulation of inﬂam-
mation. A meta-analysis of >100 studies found that IL-6
and CRP each were signiﬁcantly elevated in depressed
patients with standardised mean difference scores (d) of
0.71 and 0.26, respectively.
78 The associations remained
signiﬁcant after adjustment for body mass index (BMI)
and smoking. Moreover, IL-6 has been shown to modu-
late HPA axis function by inducing CRH release, adre-
nocorticotropic hormone synthesis and corticosteroid
production.
79 CRP production is induced by the proin-
ﬂammatory cytokines, IL-1, IL-6 and IL-17, and is thus
a non-speciﬁc marker of systemic inﬂammation.
Three blood samples will be transported to the
immunology laboratory in the Department of Surgery at
the University of Oklahoma College of Medicine for
each participant at each of the sampling time points
(sessions 1 and 7). One sample will be centrifuged to
obtain plasma which will be stored at  808C until
analysed. Serum CRP, IL-6, TNF and the other cytokines
listed above will be assayed in duplicate with ELISA (CRP
high-sensitivity kit; R&D Systems, Oxford, UK) or
enhanced cytokine bead array ﬂex kits (Becton Dick-
inson, Franklin Lakes, NJ, USA) using the manufac-
turer’s reagents and standards. The other two samples
will be used to isolate PBMCs and plasma and will be
frozen until processed. Monocytes will be isolated from
the PBMCs in order to assess mRNA levels similar to the
method used by Padmos et al.
32 This procedure utilises
monoclonal antibodies directed against human CD14 to
isolate monocytes in PBM cell suspensions. A magnetic
cell sorting system will be used for the separation of the
monocytes, and ﬂow cytometry will be used to gauge the
purity of the population. Once purity is established, total
RNA will be isolated from the monocytes using an
RNeasy kits (Qiagen, Valencia, CA, USA) according to
the manufacturer’s directions. RNA will then be reverse
transcribed to complementary DNA using standard
commercial kits. Reverse transcriptionePCRs will be
performed using the Dynamo Sybr Green HS Master Mix
(New England Biolabs, Ipswich, MA, USA) and custom
primers will be synthesised by a commercial laboratory.
Real-time reverse transcriptionePCRs will be run using
a Cepheid Smart Cycler II or similar instrument. Addi-
tional aliquots of serum and plasma will be stored so that
other inﬂammatory markers can be tested in the future
using Luminex bead arrays and/or additional available
technologies.
Source of compounds tested
Minocycline and aspirin are available on a generic basis
and are manufactured within the USA by several
companies. The identity of the active medicines and
placebos will be blinded using placebos that match the
appearance of the active drugs. The medications and
placebos have been formulated by Wedgewood Phar-
macy (Swedesboro, New Jersey, USA). The study mino-
cycline capsule and chewable aspirin tablet are identical
in appearance to their corresponding placebos.
Outcome measures and data analysis
Antidepressant response will be evaluated by assessing
changes in MADRS scores at assessment session 7 (ie,
6 weeks). Our a priori hypothesis is that minocycline
and/or aspirin plus existing medication will exert
greater antidepressant effects than placebo plus existing
medication by study completion. Assuming that there
are equal numbers of subjects in each treatment group,
this hypothesis will be statistically assessed using a group
(for the four treatment cells)-by-session (1 vs 7) repeated
measures analysis of variance (ANOVA). If the ANOVA
statistic is signiﬁcant, between- and within-group t tests
will be used in planned comparisons to identify the
nature of the effect leading to the signiﬁcant overall
ANOVA statistic. We expect to ﬁnd a signiﬁcant group-
by-session interaction, attributable to a greater reduction
in MADRS scores in the minocycline and aspirin groups
compared with the placebo group between session 1 and
session 7. If there is an imbalance in the number of
subjects across groups, (eg, due to differential dropout
rates during the ﬁrst treatment week), the data analysis
will be conducted with a mixed-effects model.
A Mixed-Effect Model Repeated Measure (MMRM)
80
will be used to derive missing data points as this method
has been shown to be superior to last observation carried
forward which can inﬂate the type I error rates.
81 The
last observation carried forward and observed cases
approaches to data imputation will be used post hoc to
provide further conﬁrmation of the results obtained
under the MMRM analysis.
In order to test whether the putative antidepressant
effects of minocycline or aspirin have a rapid onset, as
a post hoc analysis, the ANOVA will be repeated using
MADRS ratings from the assessment that follows the ﬁrst
week of exposure to active drug versus the corre-
sponding change under placebo; that is, session 2. Post
hoc tests will be performed to assess the signiﬁcance of
changes in the secondary clinical outcome measures
(QUIDS 16, HAM-A, YMRS, CGI-I).
The rate of completion in the four cells also will be
considered an outcome measure. The completion rate
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enced more by dropouts due to side effects, while the
completion rate in the placebo group may be inﬂuenced
more by dropouts due to non-response. Two different
measures of completion rate will be obtained: comple-
tion of week 1 of the study (baseline to week 1) and
completion of the study (baseline to week 6). Differ-
ences between the groups in completion rates will be
assessed with a c
2 test or a logistic regression.
We will test the hypothesis that minocycline and
aspirin reduce inﬂammation (eg, CRP, IL-6, IL-6 mRNA)
more than placebo using statistical analyses similar to
those described above. If the assay results are normally
distributed, then a group-by-session repeated measures
ANOVA with CRP, IL-6 and nine other cytokine levels as
dependent variables and BMI, smoking status and time
of blood draw as covariates will be used to assess anti-
inﬂammatory effects of minocycline and aspirin. Mixed-
effect models will be used if necessary. If the CRP or
inﬂammatory cytokine data are not normally distributed
(KolmogoroveSmirnov test) or if the equality of statis-
tical variance assumption across assessments is violated
(Levene’s test), then Friedman’s ANOVA will be used to
test for CRP or inﬂammatory cytokine differences
between groups. If the Friedman’s ANOVA statistic is
signiﬁcant, Wilcoxon sign-ranked tests will be used for
post hoc analysis of group differences. Non-speciﬁc
factors that inﬂuence CRP and inﬂammatory cytokine
levels include time of day, presence of infection, treat-
ment with anti-inﬂammatory medications, smoking,
obesity and alcohol abuse. We will attempt to control for
these potential confounds by measuring BMI and
recording NSAID and nicotine use (Universal Fager-
strom Scale) and by excluding individuals who have
recently abused substances or who have intercurrent
infections. The serum CRP concentration shows minimal
diurnal variability in adults
82 but IL-6 and other cytokine
levels vary across time of day.
83 To minimise cytokine
measurement variability due to circadian ﬂuctuations,
we will schedule patient assessment sessions at the same
time each day. Since this may not always be possible, we
will record the time of day that each blood draw is made,
divide the day into quartiles: 07:00e10:00, 10:00e12:00;
12:00e15:00 and 15:00e18:00 and use these data as
a covariate in the statistical analyses.
To test whether baseline levels of CRP and inﬂamma-
tory cytokines predict response to minocycline or
aspirin, we will subclassify the participants using
conventional criteria
84 as achieving full response ($50%
reduction in MADRS score from baseline), partial
response (<50% but $25% reduction) or non-response
(<25% reduction). Patients achieving remission (post-
treatment MADRS score #10) will also be identiﬁed. A
non-parametric alternative to the ANOVA statistic, the
ManneWhitney test, will be used to compare remitted
and non-remitted groups in baseline levels of inﬂam-
matory cytokines and CRP if the data are not normally
distributed. Ideally, the impact of baseline levels of
inﬂammation on treatment response would be tested
more rigorously using a formal stratiﬁed design.
However, in order to conduct a stratiﬁed trial with, for
example, eight experimental groups (4 3 high versus
low inﬂammation), the sample size of the study would
have to be doubled, which would signiﬁcantly increase
costs and decrease feasibility. Nevertheless, this stratiﬁ-
cation approach would be important to consider for
future studies if promising results are obtained in this
clinical trial.
Statistical power
A recent meta-analysis of 96 antidepressant treatment
studies found that the average effect size of a placebo
treatment is 1.69 compared with 2.50 for an antide-
pressant treatment.
85 We calculated that in order to
detect an effect size of 0.81 (ie, the difference between
2.50 and 1.69) with an 80% probability (two-sided test,
a¼0.05), we will require a sample size of 26 subjects per
group (http://hedwig.mgh.harvard.edu/sample_size/
size.html). This effect size may correspond to approxi-
mately three points on the MADRS. Thus, given our
sample size of 30 per group, we should have sufﬁcient
power to test speciﬁc aim 1, allowing for a 13% dropout
rate during week 1 of the study (dropouts after
completion of study week 1 will be included in the
analysis under the MMRM approach described above).
As discussed above, a recent meta-analysis
78 of cross-
sectional studies of serum-derived IL-6 and CRP in
depression calculated effect sizes of 0.71 for IL-6 and
0.26 for CRP. Based on these effect sizes, a sample size of
26 would yield >80% probability of detecting signiﬁcant
depression-related changes in IL-6 but only a 60%
probability of detecting a depression-related change in
CRP. There are three reasons why we believe that these
CRP power estimations are not applicable to this study.
First, the effect sizes derived from the meta-analysis are
based on cross-sectional studies. Given the effect of
variables such as smoking, diet, exercise and BMI on
proinﬂammatory cytokines, a within-subjects design is
likely to reduce non-depression-related sources of vari-
ance and substantially increase statistical power. Second,
we are examining the effect of mood on IL-6 and CRP
levels and are treating patients with minocycline and
aspirin, drugs known to possess anti-inﬂammatory
properties. We therefore suggest that our proposed study
is likely adequately powered to detect any true changes
in plasma IL-6, CRP and the other inﬂammatory
cytokines across treatment blocks.
Regarding IL-6 mRNA gene expression in PBMs,
Padmos et al
32 reported a 38-fold increase in IL-6 mRNA
levels in unmedicated patients with BD compared with
HC. Since minocycline reduces IL-6 levels (see above),
we expect our study to have very high power to detect
differences between groups, as well as changes in
response to minocycline. The simultaneous detection
of nine other inﬂammation-related cytokines, in addi-
tion to IL-6 (using newer more sensitive technology),
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inﬂammatory cascades than that measured in previous
studies.
ETHICS AND DISSEMINATION
Gender/minoritypaediatricc inclusion for research
Women and minorities will be included in the study
without prejudice according to their representation in
the study population. Participants will be recruited from
the greater metropolitan areas of Tulsa, Oklahoma, and
Wichita, Kansas, and efforts will be made to ensure that
our subject population resembles the gender, ethnic and
racial composition of these areas.
Exclusion criteria
The following exclusion criteria apply: (1) inability to
provide informed consent; (2) age of onset of BD>40
years; (3) serious risk of suicide; (4) current delusions or
hallucinations sufﬁcient to interfere with the capacity to
provide informed consent; (5) current manic symptoms
(depressed BD patients with concurrent manic symp-
toms have been found to be more likely to experience
adverse reactions in antidepressant treatment trials
86);
(6) medical illness including as hepatic impairment,
renal dysfunction, bleeding diatheses (eg, hemophilia),
cerebrovascular disease or heart disease, hypertension
that is inadequately controlled by medication, diabetes
mellitus or known peptic ulcer disease; (7) abuse of
drugs or alcohol within the preceding 6 months or
substance dependence within the last 5 years; (8) daily
alcoholic beverage consumption equivalent to $3 oz. of
alcohol; (9) asthma or known allergies or hypersensitiv-
ities to tetracycline antibiotics, aspirin or other NSAIDs;
(10) current use of drugs that could increase the risks
associated with aspirin or minocycline administration,
namely other antibiotic medications, other NSAIDs or
anticoagulants (eg, warfarin), acetazolamide or metho-
trexate; (11) known HIV or other chronic infection
including but not limited to viral hepatitis and (12)
pregnant or nursing women and women who are
attempting to conceive during the 6-week study period
will also be excluded.
Specimens, records and data collection
A physician, registered nurse or trained phlebotomist
will utilise a sterile technique to draw 60 ml of blood by
venipuncture. Participants will also be asked to submit
a urine sample. A physician, registered nurse or trained
technician will collect electrocardiogram data from the
subject in a private exam room.
Recruitment and consent procedure
Volunteers will be recruited from the community as
well as from the clinical services at the Laureate Psychi-
atric Clinic and Hospital and the Oklahoma University
School of Community Medicine in Tulsa, Oklahoma,
USA, and from the clinical services afﬁliated with the
KUMCRI. Volunteers may be referred from sources that
include physicians, newspaper advertising, self-help
organisations, self-referral and WIRB-approved ﬂyers
posted at local universities, schools, churches and
grocery stores. Participants may be prescreened through
screening protocols based at LIBR or KUCRI. We plan to
recruit a total of 120 participants.
All participant interactions including consenting will
be conducted in private interview/exam rooms. These
rooms are secured from public areas via combination
locked doors that are only accessible to authorised
personnel. Prospective participants will receive an
explanation of the objectives, procedures and hazards of
this protocol that is appropriate to their level of under-
standing. The right of the subject to decline to partici-
pate or to withdraw from the study at any time will be
made clear.
Non-English speaking participants will not be
recruited.
After the consent form is verbally explained to the
participant and any questions have been answered, the
researcher will leave the room to allow the participant to
read the consent form thoroughly. Family members will
be allowed to be present and to discuss the consenting
process with the participant. After the consent is read,
the researcher will return and answer any additional
questions the participant may have. The researcher will
remind the subject that participation is strictly voluntary
and that they have the right to withdraw at any time.
Participants will be asked to arrive 30 min early in order
to have sufﬁcient time for the consenting process.
Subject risks
The risks of behavioural testing are minimal. The risks of
blood drawing are also minimal. Possible mild side
effects of the blood draw include mild pain or bruising at
the site of the venipuncture.
Minocycline has been used a broad-spectrum antibi-
otic for many years in doses up to 400 mg/day.
34 It has
been used on a chronic basis to treat acne and RA, often
for many years, in hundreds of thousands of patients.
The most commonly encountered side effects are upset
stomach, diarrhoea, dizziness, drowsiness, ataxia, vertigo,
headache and vomiting. Prolonged use can be associated
with pigmentation of the skin, gums or teeth. Between
1975 and 2006, the WHO Collaborating Center for
International Drug Monitoring listed 122 cases of
adverse drug reactions to intravenous minocycline; most
commonly, abnormal hepatic function and thrombocy-
topaenia.
34 These included cases of serious liver injury,
including irreversible drug-induced hepatitis and fulmi-
nant hepatic failure that was fatal in two cases, thought
to be due to triggering or unmasking autoimmune
hepatitis. One case of autoimmune-related glomerulo-
nephritis has been reported. The role of oral minocy-
cline in precipitating these conditions has not been
clearly established. Minocycline also has been associated
with idiopathic intracranial hypertension (pseudotumor
cerebri). Long-term trials have shown that minocycline is
well tolerated. In a 2-year trial of minocycline (200 mg/
10 Savitz J, Preskorn S, Teague TK, et al. BMJ Open 2012;2:e000643. doi:10.1136/bmjopen-2011-000643
Minocycline and aspirin in the treatment of bipolar depressionday) for RA, three of 30 patients withdrew due to
ﬁngernail discolouration, dizziness or erythematous
rash.
54 Of 11 patients with HD treated with minocycline
(100 mg/day) for 2 years, one complained of nausea in
the ﬁrst 3 weeks and two of sedation,
53 while in a 6-month
trial of minocycline for amyotrophic lateral sclerosis, the
mean tolerated dose was 387 mg/day and the most
common adverse effects were GI.
87 Five of 36 patients
with schizophrenia withdrew from a 6-month trial of
minocycline (200 mg/day) due to indigestion (n¼2),
pigmentation (n¼2) or a suicide attempt (n¼1).
58
Low-dose aspirin has been safely used in many millions
of patients on a worldwide scale for its role as an
antithrombotic and thrombolytic. A meta-analysis of
>100 randomised trials in high-risk patients indicated
that low-dose ASA reduced CV death by 15% and
prevented non-fatal vascular events by about 30%.
88
These data stand in striking contrast to the data obtained
in COX-2 inhibitors, which can increase CV risk. In
clinical trials of several COX-2 selective and non-selective
NSAIDs of up to 3 years duration have shown an
increased risk of serious CV thrombotic events, myocar-
dial infarction and stroke, which have in many cases been
fatal.
89 Patients with known CV disease or risk factors for
CV disease are at greater risk for such events during
chronic treatment with COX-2 inhibitors. Evidence from
human pharmacology and genetics, genetically manipu-
lated rodents and other animal models and randomised
trials indicates that this is consequent to suppression
of COX-2-dependent cardioprotective prostaglandins,
particularly prostacyclin.
90
Aspirin does not cause a generalised bleeding abnor-
mality unless given to patients with an underlying
haemostatic defect (eg, haemophilia, uraemia or that
induced by anticoagulant therapy). Aspirin-induced
impairment of primary haemostasis cannot be separated
from its antithrombotic effect and is similar at all doses
$75 mg/day.
91 The risk of intracranial bleeding is
exceedingly rare (<0.1% in high-risk populations) but is
higher in individuals with cerebrovascular disease.
88
Hypertension that is inadequately controlled by medi-
cation often is considered a contraindication to aspirin
because of the concern that possible beneﬁts in the
prevention of CV events may be counterbalanced by an
increased risk of cerebral bleeding. However, hyperten-
sive patients whose blood pressure is well controlled
appear protected from myocardial infarction by aspirin
therapy without an increase in the number of cerebral
haemorrhages or strokes.
92 Moreover, aspirin therapy
does not affect blood pressure or the response of
hypertension to antihypertensive agents.
91 93
NSAIDs as a class can cause serious GI adverse events
including inﬂammation, bleeding, ulceration and
perforation of the stomach, small intestine or large
intestine, which rarely have proven fatal. In controlled
clinical trials, the percentage of patients reporting one
or more GI complaints has ranged from 4% to 16%.
91
The mechanism underlying this adverse effect appears
attributable to the inhibition of COX-1. Thus, the inci-
dence of GI side effects has been higher for NSAIDs with
more potent effects at COX-1, such as aspirin and
indomethicin. For example, in controlled trials, the
incidence of GI side effects for aspirin and indometh-
acin has been about twice as high as that for ibuprofen,
a non-selective COX inhibitor, in equally effective doses
for arthritis. Nevertheless, the incidence of GI side
effects associated with aspirin is dose dependent and
thus is markedly lower when using aspirin in the low-
dose range planned for the current study. Notably, the
risk of GI bleeding is not reduced by using the enteri-
cally coated aspirin formulations but is thought to be
lower during concomitant use of omeprazole.
91 The
effects of warfarin and NSAIDs on GI bleeding are
synergistic such that the users of both drugs together
have a risk of serious GI bleeding higher than users of
either drug alone. Fortunately, the risk of GI bleeding,
which reﬂects the inhibition of prostaglandins in the
stomach (from systemic rather than local exposure), is
much smaller when using low-dose as opposed to
high-dose aspirin.
Low-dose aspirin has not been reported to alter renal
function and does not reduce effectiveness of ACE
inhibitors for HTN (in contrast to other NSAIDs).
93 94
However, aspirin can inhibit the renal clearance of
acetazolamide and methotrexate potentially leading to
increased blood concentrations of and toxicity from
these agents. Salicylate can displace other drugs which
are protein bound, especially phenytoin and valproic
acid, increasing their free drug concentrations in
plasma. This may increase side effects, toxicity and/or
efﬁcacy for displaced drugs. If the BD subjects are
currently receiving valproic acid preparations (eg,
divalproex), then the plasma levels of these agents will
be monitored for potential changes.
Aspirin may cause a severe allergic reaction that may
include hives, asthma (wheezing), facial swelling and
shock. Aspirin overdose can be fatal at 30 g or higher.
In sum, we believe that our 232 design is appropriate
for trials involving experimental drugs that already have
been well studied with respect to toxicity, as is the case
with aspirin and minocycline. A parallel arm design, as
opposed to a 232 factorial design, would be more clearly
informative in the case of an experimental drug for
which the toxicity and drug interaction potential have
not been thoroughly studied in human subjects.
Protected Health Information protection
Paper copies of consents, screening forms, the Research
Privacy Form and any other forms, testing results or
papers containing Protected Health Information (PHI),
will be stored in a secured medical records room with
access granted only to authorised personnel.
Electronic data that contain PHI will be managed in
accordance with ISO 27000 series information security
standards with policies developed from current NIST
guidelines (SP 800-66) for HIPAA and HITECH
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PHI are derived from NIST 800-122 and include (but not
limited to) the following:
1. Access Enforcement (AC-3)dIndividual user
accounts, role based access control, access control lists;
2. Separation of Duties (AC-5)dde-identiﬁcation of data
as appropriate, acquire/analyze/manage ﬁrewall;
3. Least Privilege (AC-6)dto ensure PHI data is only
available to persons with established need for access;
4. Remote Access (AC-17)dSecure VPN, encrypted end
devices;
5. Access Control for Mobile Devices (AC-19)d
Password login, remote destruction capabilities;
6. Auditable Events (AU-2) + Monitoring: Log detailed
server and network information, alert for problems;
7. Analysis, and Reporting (AU-6)dProcedures to audit
system records for inappropriate activity.
8. User Identiﬁcation and Authentication (IA-2)d
username/secure password and two factor authenti-
cation will be required when appropriate.
9. Media Access, Marking, Storage, and Transport (MP-
2,3,4,5)dRecords will be asset tagged and marked to
their PHI status, PHI data will be secured and
managed by professional system administrators and
will be transported via encryption (VPN, USB, File);
10. Media Sanitization (MP-6)dData will be destroyed
by SFHS in accordance with their policies and
procedures;
11. Transmission Conﬁdentiality (SC-9)dEncryption
will be used when needed for all avenues of data
transmission (wireless, network, etc).
To protect subject conﬁdentiality, blood samples will
be anonymized as follows:
1. Last name: All participants will be assigned the last
name ‘LIBR.’
2. First name: The ﬁrst name will be a secure alpha
cryptographic hash based on LIBR user ID. This
technique is the gold standard in computer security
for one-way correlation of data.
Beneﬁts versus risks
The participant may beneﬁt from participation if either
study drug produces an antidepressant effect. Partici-
pants will also receive a free clinical evaluation; more
frequent treatment visits than are typical in practice,
diligent follow-up in terms of symptoms and side effects
and physical and psychiatric monitoring during the
study. The risks of delaying alternative treatments are
minimal in relation to the potential long-term beneﬁts
to the subjects and the importance of knowledge that
may reasonably result. The importance of the knowledge
that will likely be gained from this study clearly exceeds
the associated potential risks.
Alternative treatment
It is possible that some patients may feel better with
talk therapy. Participating in any type of talk therapy
with their psychiatrist or psychologist does not require
dropping out of this study. Subjects will be encouraged
to contact the study investigators, particularly the physi-
cian in the study, with any questions they may have
regarding alternatives to treatment through this research
study. The study investigators will assist in referring the
subject to another physician for treatment after their
participation in the study has ended.
Physical and psychological testing, blood draws, urine
samples and electrocardiogram data provide no known
risks to persons other than those listed in the exclusion
criteria, whereas the combinatory power of these
measures may provide information relevant to under-
standing the pathophysiology of BD.
Data and safety monitoring plan
This study involves more than minimal risk. The study
progress will be overseen by a Data, Safety and Moni-
toring Board. The Data, Safety and Monitoring Board is
composed of three members who will meet in person
or per telephone at least once every 6 months to
review relevant study data including adverse events and
dropout rates.
Any unanticipated adverse events will be reported
immediately to the IRB of record and to the LIBR
Human Protection Administrator. Any adverse events
will be included in the annual IRB report.
Dissemination of results
The study results will be presented at national and/
or international biomedical scientiﬁc meetings and
published in peer-reviewed journals.
REGISTRATION
In accordance with the recommendations of the Inter-
national Committee of Medical Journal Editors,
95 the
proposed trial is registered in a public registry (http://
www.clinicaltrials.gov/, Identiﬁer: NCT01429272).
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